Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
169 Leser
Artikel bewerten:
(1)

Akkodis Acquires Raland Compliance Partners and Expands Life Sciences Consulting Capabilities

Finanznachrichten News

The acquisition will further strengthen the global Smart Industry leader's footprint in the Life Sciences industry, enabling it to provide clients with enhanced services offerings.

Akkodis Acquires Raland Compliance Partners and Expands Life Sciences Consulting Capabilities

ZURICH, Jan. 23, 2025 /PRNewswire/ -- Akkodis, a global digital engineering company and Smart Industry leader, today announced that it has acquired US-based Raland Compliance Partners, LLC (Raland), a specialist provider of quality and regulatory compliance services to the Life Sciences industry. This expansion will enable Akkodis to deliver even more value to its clients in this key industry.

Raland was founded in 2002 and is headquartered in Chicago, Illinois, with offices and resources strategically placed across the country to serve its clients. Over the past 23 years, the company has become a well-regarded provider of services to pharma, biotech and medical device verticals with a high standard of performance and an international client portfolio. This acquisition will expand the organization's consulting services footprint and expertise in the Life Sciences & Healthcare industry in the US and around the world.

"We are thrilled to welcome Raland's talented team to the Akkodis family," said Mike Small, US Country President, The Adecco Group & President, Akkodis NA. "The company's proven expertise and leadership in the Life Sciences sector perfectly complement our vision of driving innovation and transformation in this critical industry. This acquisition is a significant step forward in expanding the breadth and depth of our consulting services and solidifying our ability to deliver exceptional value to clients worldwide."

Kevin McLeod, Head of Engineering at Akkodis/Entegee added, "Having worked alongside Raland in various capacities over many years, my team has seen firsthand their outstanding reputation and deep knowledge in medical consulting services. This acquisition opens exciting opportunities for collaboration within our Life Sciences segment and across the broader Akkodis portfolio."

Tom Rynkiewicz, Vice President, Life Sciences Regulatory and Quality Assurance, Raland, commented, "We are honored to join the Akkodis family, marking a pivotal moment for our company. I am immensely proud of our talented team of experts who have consistently delivered excellence in quality and regulatory compliance services, establishing a strong presence within the Life Sciences sector." He continued, "This acquisition positions Raland to continue to provide our uncompromised level of service to existing customers and to deliver greater innovation, scalability, and impact across a broader spectrum of client needs."

The transaction closed earlier this month.

Media contacts

Anne Friedrich
SVP, Global Head of Communications, Akkodis
E. anne.friedrich@akkodis.com

Lisa Bushka
VP, External Communications, Akkodis
E. lisa.bushka@adeccogroup.com

About Akkodis

Akkodis is a global digital engineering company and Smart Industry leader. We enable clients to advance in their digital transformation with Consulting, Solutions, Talent, and Academy services. Headquartered in Switzerland and part of the Adecco Group, Akkodis is a trusted tech partner to the world's industries. We co-create and pioneer solutions that help to solve major challenges, from accelerating the clean energy transition and green mobility, to improving user and patient centricity. Empowered by a culture of inclusion and diversity, our 50,000 tech experts across 30 countries combine best-in-class technologies and cross industry knowledge to drive purposeful innovation for a more sustainable tomorrow. We are passionate about Engineering a Smarter Future Together. akkodis.com | LinkedIn | Instagram | Facebook | X

About the Adecco Group

The Adecco Group is the world's leading talent company. Our purpose is making the future work for everyone. Through our three global business units - Adecco, Akkodis and LHH - across 60 countries, we enable sustainable and lifelong employability for individuals, deliver digital and engineering solutions to power the Smart Industry transformation and empower organisations to optimise their workforces. The Adecco Group leads by example and is committed to an inclusive culture, fostering sustainable employability, and supporting resilient economies and communities. The Adecco Group AG is headquartered in Zurich, Switzerland (ISIN: CH0012138605) and listed on the SIX Swiss Exchange (ADEN). www.adeccogroup.com

Photo - https://mma.prnewswire.com/media/2604003/Akkodis_X_Raland.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/akkodis-acquires-raland-compliance-partners-and-expands-life-sciences-consulting-capabilities-302357793.html

© 2025 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.